One of the most universally agreed upon methods for ensuring data validity in clinical trials is the process of blinding. And It’s well accepted that an unintentional unblinding can have serious ramifications for data integrity.
However, there are specific aspects related to unblinding, including how and when it may occur, that aren’t as obvious or universally agreed upon.
Join Calyx’s Head of Statistics and Product Support Services, Malcolm Morrissey, for a webinar focusing on an undervalued aspect of study and IRT design which:
- Has the potential to unblind multiple patients
- Applies to all double-blind trials
- Has implications for study management
- Has implications for supplies management
After a brief presentation, Malcolm opens the floor to your questions – ask him anything!
Associate Director, Statistics and Product Support Services, Calyx
Malcolm Morrissey obtained a PhD in Statistical Inference in 2001 and since has had broad experience as a research associate, statistician, and manager in the pharmaceutical industry. He joined Calyx in 2005 and currently manages a team whose duties include supporting and developing randomization and medication management algorithms for clinical trials managed by IRT.